Bevacizumab in Oncology: Boon or Bane.

For the remaining treatment applications of bevacizumab: metastatic breast cancer, renal cell carcinoma, and glioblastoma multiforme, various clinical trials have failed to show a significant benefit in overall survival. Bevacizumab is a recombinant humanized monoclonal antibody against vascular endothelial growth factors (VEGF). It is approved for a range of solid cancers such as ovarian cancer, colorectal cancer, glioblastoma multiforme, advanced non-squamous non-small cell lung cancer (NSCLC), cervical cancer, renal cell carcinoma, and metastatic breast cancer. [Extracted from the article]